121 related articles for article (PubMed ID: 106625)
1. Interferon therapy in multiple myeloma.
Ideström K; Cantell K; Killander D; Nilsson K; Strander H; Willems J
Acta Med Scand; 1979; 205(3):149-54. PubMed ID: 106625
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma first observed as multiple cutaneous plasmacytomas.
Shah A; Klimo P; Worth A
Arch Dermatol; 1982 Nov; 118(11):922-4. PubMed ID: 6814367
[TBL] [Abstract][Full Text] [Related]
3. [Aggressive transformation and extramedullary tumor formation in IgA-lambda multiple myeloma].
Tanigawa M; Tamaki S; Fujieda A; Miyashita H; Tanaka K; Ichioka M; Taniguchi M; Tsuji K; Miyanishi E
Rinsho Ketsueki; 2000 Aug; 41(8):635-40. PubMed ID: 11020990
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.
Matzner Y; Benbassat J; Polliack A
Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296
[No Abstract] [Full Text] [Related]
5. Multiple myeloma and acute leukemia associated with alkylating agents.
Kyle RA; Pierre RV; Bayrd ED
Arch Intern Med; 1975 Jan; 135(1):185-92. PubMed ID: 1053891
[TBL] [Abstract][Full Text] [Related]
6. [Vacuolar inclusions with multivesicular structure in leukemic multiple myeloma].
Fujii H; Nakagawa H; Kanoh T; Matsuyama F; Urata Y
Rinsho Ketsueki; 1992 Aug; 33(8):1090-4. PubMed ID: 1328702
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of leukemias and lymphomas with interferons: I. Trial of myeloma therapy with human beta-interferon].
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Hayat M; Jasmin C; Schwarzenburg L; Machover D; Ribaud P; De Vassal F; Horosezewicz JS
Biomed Pharmacother; 1982 Jan; 36(1):55-9. PubMed ID: 6181822
[TBL] [Abstract][Full Text] [Related]
8. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
Ringborg U; Lewensohn R
Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
[TBL] [Abstract][Full Text] [Related]
9. Interferons in the treatment of multiple myeloma.
Cooper MR; Welander CE
Semin Oncol; 1986 Sep; 13(3):334-40. PubMed ID: 2429367
[No Abstract] [Full Text] [Related]
10. Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma--a "France autogreffe" study.
Colombat P; Milpied N; Laporte JP; Casassus P; Linassier C; Harousseu JL
Cancer; 1994 Dec; 74(11):2930-4. PubMed ID: 7954256
[TBL] [Abstract][Full Text] [Related]
11. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Westin J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
[TBL] [Abstract][Full Text] [Related]
12. [Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan].
Morlock G; Bataille R; Sany J; Serre H
Sem Hop; 1977 Apr 9-16; 53(14-15):853-6. PubMed ID: 194338
[No Abstract] [Full Text] [Related]
13. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
14. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients.
Petrucci MT; La Verde G; Ribersani M; Avvisati G; Mandelli F
Leuk Lymphoma; 2000 Sep; 39(1-2):131-8. PubMed ID: 10975391
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial.
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Hayat M; Jasmin C; Schwarzenberg L; Machover D; Ribaud P; De Vassal F; Horoszewicz JS
Anticancer Res; 1982; 2(1-2):63-6. PubMed ID: 6180675
[TBL] [Abstract][Full Text] [Related]
16. [Pleural effusion as a first sign of Ig D lambda multiple myeloma].
Maachi M; Fellahi S; Diop ME; Francois T; Capeau J; Bastard JP
Ann Med Interne (Paris); 2003 Feb; 154(1):70-2. PubMed ID: 12746663
[TBL] [Abstract][Full Text] [Related]
17. Melphalan in multiple myeloma.
Hoogstraten B; Sheehe PR; Cuttner J; Cooper T; Kyle RA; Oberfield RA; Townsend SR; Harley JB; Hayes DM; Costa G; Holland JF
Blood; 1967 Jul; 30(1):74-83. PubMed ID: 6028709
[No Abstract] [Full Text] [Related]
18. [Multiple myeloma of IgG-lambda type associated with asymptomatic primary biliary cirrhosis].
Fujii H; Yashige H
Rinsho Ketsueki; 1989 Oct; 30(10):1886-91. PubMed ID: 2512398
[TBL] [Abstract][Full Text] [Related]
19. Treatment of plasma cell myeloma with cytotoxic agents.
Bergsagel DE; Pruzanski W
Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous occurrence of clinical manifestations of myeloma and Waldenström's macroglobulinemia with monoclonal IgG Lambda and IgM Kappa in a single patient.
Fine JM; Gorin NC; Gendre JP; Petitpierre JC; Labro-Bryskier MT; Lambin P
Acta Med Scand; 1981; 209(3):229-34. PubMed ID: 6784449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
